PGEN — Precigen, Inc.
Is PGEN overbought or oversold? Here is the current MarketMoodz read.
Precigen, Inc. (PGEN) currently reads Neutral on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $4.30. The rating moved from Oversold to Neutral on November 10, 2026.
- Public ratingNeutral (as of November 17, 2026)
- Last close$4.30
- Last changeMoved from Oversold to Neutral on November 10, 2026
- SectorHealthcare
- IndustryBiotechnology
AI analysis
Precigen, Inc. combines a differentiated cell/gene therapy platform and an early-stage pipeline with near-term clinical readouts that could materially move valuation. The company lacks significant commercial revenue and appears dependent on financing or partnership activity to sustain operations, which raises dilution risk. Market conditions favoring growth names provide an environment where strong clinical data could produce outsized gains, but the path is binary and subject to regulatory, manufacturing and competitive execution risks. In the near term, share performance is likely to be driven by trial newsflow, cash runway updates and any partnership announcements; absent positive catalysts, expect limited appreciation and elevated volatility.
Key factors
- Platform and pipeline exposure: cell and gene therapy programs including T-cell platforms that could deliver step-change clinical outcomes if pivotal data are positive.
- Near-term clinical catalysts: upcoming readouts and IND/clinical progress that could re-rate the equity on positive results.
- Limited commercial revenue: company remains early-stage with little to no recurring product revenue, making valuation sensitive to binary trial outcomes and financing.
- Balance sheet and financing needs: historical use of equity/convertible securities in the sector implies potential dilution risk absent sustained cash inflows or partnerships.
- Sector sentiment: growth-favoring market flows into biopharma and large-cap pharma defensive positioning could leave small-cap biotech dependent on idiosyncratic newsflow.
- Partnership/licensing optionality: potential for partnerships or asset sales to de-risk programs and extend runway.
Risks
- Clinical binary risk: negative or inconclusive trial results could sharply reduce valuation.
- Dilution and convertible-debt pressure: need for capital may require equity issuance or dilutive financing.
- Regulatory risk: delays, additional data requests, or manufacturing/regulatory hurdles could push timelines and increase costs.
- Commercial execution and manufacturing scale: limited commercial history increases execution risk if a program advances toward approval.
- Competitive landscape: competing cell/gene therapies or alternative modalities could reduce addressable market and pricing power.
- Market liquidity and sentiment swings: small-cap biotech shares can be volatile and sensitive to macro shifts and sector rotations.
See today's live rating, score and targets
Members see the live hourly rating for PGEN — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.